Skip to Content

The Cigna Group

CI: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$147.00ZqqxkcVrzlftfwh

Cigna Earnings: Solid Trends Boost Outlook and Fair Value, Despite Regulatory Scrutiny on PBM

Narrow-moat Cigna turned in solid first-quarter results, and the firm mildly increased its 2023 outlook. Considering these solid trends and cash flow generated since our last valuation change, we are boosting our fair value estimate 7% to $344 per share. Shares remain moderately undervalued, probably reflecting some of the renewed regulatory risks to its pharmacy benefit management, or PBM, operations. However, we think those risks will be manageable over time.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CI so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center